Is it Finally Time to Buy Medical Properties Trust?
Medical Properties Trust (NYSE:MPW) is a REIT that focuses on…
Buy
62
BCAX Quote, Financials, Valuation and Earnings
Last price:
$13.41
Seasonality move
:
--
Day range:
$13.03 - $14.39
52-week range:
$11.10 - $28.09
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
310.5K
Avg. volume:
538.8K
1-year change:
--
Market cap:
$616.7M
Revenue:
--
EPS (TTM):
-$0.20
Analysts' Opinion
-
Consensus RatingBicara Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $39.44, Bicara Therapeutics has an estimated upside of 194.31% from its current price of $13.40.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $31.00 representing -131.34% downside risk from its current price of $13.40.
Fair Value
-
According to the consensus of 4 analysts, Bicara Therapeutics has 194.31% upside to fair value with a price target of $39.44 per share.
BCAX vs. S&P 500
-
Over the past 5 trading days, Bicara Therapeutics has overperformed the S&P 500 by 2.78% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Bicara Therapeutics does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bicara Therapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Bicara Therapeutics reported revenues of --.
Earnings Growth
-
Bicara Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Bicara Therapeutics reported earnings per share of --.
Enterprise value:
412.9M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-8.96x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-29 | 2024-03-29 | 2024-03-29 | |||
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | -- | -- | -- | -- | -- | |
| Period Ending | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | -- | $206.1M | |
| Total Assets | -- | -- | -- | -- | $208.8M | |
| Current Liabilities | -- | -- | -- | -- | $16.1M | |
| Total Liabilities | -- | -- | -- | -- | $383.6M | |
| Total Equity | -- | -- | -- | -- | -$174.8M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-29 | 2024-03-29 | 2024-03-29 | |||
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
BCAX
Sector
Market Cap
$616.7M
$36.5M
Price % of 52-Week High
47.7%
44.66%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.9%
1-Year Price Total Return
--
-39.9%
Beta (5-Year)
--
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$13.18
200-day SMA
Buy
Level
$0.00
Bollinger Bands (100)
Sell
Level
12.32 - 20.16
Chaikin Money Flow
Sell
Level
-4.8M
20-day SMA
Sell
Level
$13.57
Relative Strength Index (RSI14)
Sell
Level
49.87
ADX Line
Buy
Level
12.39
Williams %R
Neutral
Level
-62.3711
50-day SMA
Buy
Level
$12.96
MACD (12, 26)
Sell
Level
-0.07
25-day Aroon Oscillator
Buy
Level
24
On Balance Volume
Neutral
Level
2M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
--
Momentum Score
Level (--)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
Stock Forecast FAQ
In the current month, BCAX has received 4 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BCAX average analyst price target in the past 3 months is $39.44.
-
Where Will Bicara Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bicara Therapeutics share price will rise to $39.44 per share over the next 12 months.
-
What Do Analysts Say About Bicara Therapeutics?
Analysts are divided on their view about Bicara Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bicara Therapeutics is a Sell and believe this share price will drop from its current level to $31.00.
-
What Is Bicara Therapeutics's Price Target?
The price target for Bicara Therapeutics over the next 1-year time period is forecast to be $39.44 according to 4 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BCAX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bicara Therapeutics is a Buy. 4 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BCAX?
You can purchase shares of Bicara Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bicara Therapeutics shares.
-
What Is The Bicara Therapeutics Share Price Today?
Bicara Therapeutics was last trading at $13.41 per share. This represents the most recent stock quote for Bicara Therapeutics. Yesterday, Bicara Therapeutics closed at $13.40 per share.
-
How To Buy Bicara Therapeutics Stock Online?
In order to purchase Bicara Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Signet Jewelers Stock Go Up So Much?
Signet Jewelers (NYSE:SIG) is the largest diamond retailer in the…
Why Did HealthEquity Stock Fall So Much?
HealthEquity (NASDAQ:HQY) is a fintech company that acts as an…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Sell
41
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Buy
78
AJINY alert for Mar 29
Ajinomoto [AJINY] is up 99.61% over the past day.
Buy
74
SLNO alert for Mar 28
Soleno Therapeutics [SLNO] is up 6.8% over the past day.
Buy
69
AGX alert for Mar 29
Argan [AGX] is up 19.83% over the past day.
